Kairos Pharma Ltd (KAPA) Stock Analysis
Verdict: AVOID
Pre-revenue biotech faces severe cash burn and pending 1-for-7 reverse split dilution; downside risks far outweigh speculative pipeline upside.
Investment score: 20/100
Analysis as of
Is Kairos Pharma Ltd stock worth reviewing? AI model thesis
The AI model assigns an AVOID recommendation to Kairos Pharma Ltd (KAPA) due to terminal cash runway pressure, active capital restructuring via a 1-for-7 reverse stock split, and zero current revenue generation.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Kairos Pharma Ltd opportunities and risks
What speaks for KAPA
- Clinical pipeline progression in cancer drug resistance
What speaks against KAPA
- Terminal cash runway exhaustion within 8 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KAPA | n/a | 0.0x | n/a | 0.0% | 0.0% | -79.9% |
| DRMA | n/a | 0.0x | 0.4x | 0.0% | 0.0% | -733.2% |
| LIMN | n/a | 0.0x | n/a | 0.0% | 0.0% | -63.5% |
| CDIO | n/a | 394.3x | n/a | -555.0% | -44771.8% | -102.5% |
| XBIO | n/a | 2.7x | n/a | 100.0% | -75.9% | -26.5% |
| BRTX | n/a | 15.2x | n/a | 92.1% | -3089.6% | -219.0% |
| Peer median | n/a | 2.7x | n/a | 0.0% | -75.9% | -102.5% |
Frequently asked questions about Kairos Pharma Ltd (KAPA)
Is KAPA stock a good investment?
The cached TradeMates AI model rates Kairos Pharma Ltd as AVOID with an investment score of 20/100. The AI model assigns an AVOID recommendation to Kairos Pharma Ltd (KAPA) due to terminal cash runway pressure, active capital restructuring via a 1-for-7 reverse stock split, and zero current revenue generation. This is algorithmic model output, not personal investment advice.
Is KAPA stock a buy?
The TradeMates model verdict for KAPA is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.